Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache.

摘要

To the Editor: Weatherall et al. recently reported on IV aspirin for the inpatient management of headache. In the introduction, the authors stated "Clinically, the ASAUMAMIG study2 demonstrated that IV aspirin was effective and well-tolerated in the treatment of acute migraine attacks, indeed comparable to subcutaneous sumatriptan."I disagree. The ASAUMAMIG study was a randomized, double-blind, placebo-controlled trial and used double-dummy technique.1 Subcutaneous sumatriptan (6 mg) was compared to IV aspirin (1 g or lysine acetylsalicylate 1.8 g) and placebo. Sumatriptan was superior (91.2% [104/114]) to aspirin (73.9% [88/119]) for headache relief; headache decreased from moderate or severe to none or mild after 2 hours. A total of 76.3% (87/114) of patients in the sumatriptan group and 43.7% (52/ 119) from the aspirin group were pain-free after 2 hours.